22 completed, 10 terminated, 2 recruiting, 2 unknown. 36 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Completed 22, Terminated 10, Recruiting 2, Unknown 2 |
| Phase 2 | 8 | Terminated 4, Completed 2, Unknown 2 |
Follow Sunitinib Malate: new trials by email Literature Review of Sunitinib Malate trials Research Report on Sunitinib Malate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 24 | 2024-08-14 | 2026-10-20 |
| Losartan + Sunitinib in Treatment of Osteosarcoma Losartan, Sunitinib - Osteosarcoma | Phase 1 | Recruiting | University of Colorado, Denver | 41 | 2019-08-26 | 2026-09-01 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Graybug Vision | 32 | 2017-08-29 | 2019-12-20 |
| Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | OHSU Knight Cancer Institute | 7 | 2016-01-13 | 2020-05-26 |
| Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) Nivolumab, Pazopanib, Sunitinib - Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma | Phase 1 | Completed | Bristol-Myers Squibb | 194 | 2012-02-09 | 2021-12-02 |
| Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies sunitinib malate, bevacizumab, pharmacological study - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 6 | 2010-10-01 | 2014-04-02 |
| Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) Sunitinib, Temsirolimus - Renal Cell Cancer, Kidney Cancer | Phase 1 | Completed | M.D. Anderson Cancer Center | 23 | 2010-05-01 | 2015-11-18 |
| Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy Hydroxychloroquine, Laboratory Biomarker Analysis, Pharmacological Study - Adult Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2010-02-19 | 2023-08-02 |
| Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery Dalteparin, Pharmacological Study, Sunitinib Malate - Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 16 | 2010-02-06 | 2022-08-05 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients sunitinib malate, docetaxel, prednisone - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 1 / Phase 2 | Terminated | John P. Fruehauf | 4 | 2009-07-01 | 2017-02-01 |
| Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer exemestane, sunitinib malate, placebo - Breast Cancer | Phase 1 / Phase 2 | Unknown | Institut Català d'Oncologia | 70 | 2009-03-01 | 2013-08-12 |
| Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma sunitinib malate, temozolomide - Metastatic Melanoma | Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 16 | 2008-12-01 | 2020-08-03 |
| Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors Ixabepilone, Sunitinib - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Jaime Merchan | 36 | 2008-11-01 | 2015-10-09 |
| Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery sunitinib malate, gene expression analysis, reverse transcriptase-polymerase chain reaction - Kidney Cancer | Phase 1 | Terminated | Harry Drabkin | 17 | 2008-10-01 | 2015-10-22 |
| Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma Sunitinib malate, Radiotherapy - Soft Tissue Sarcoma | Phase 1 / Phase 2 | Unknown | Australasian Sarcoma Study Group | 26 | 2008-09-01 | 2011-06-23 |
| Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer 5-fluorouracil, cisplatin, sunitinib malate - Stomach Neoplasms | Phase 1 | Completed | Pfizer | 34 | 2008-08-01 | 2011-12-19 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2008-07-01 | 2013-07-02 |
| Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome Sunitinib Malate - Von Hippel-Lindau Syndrome | Phase 1 / Phase 2 | Terminated | National Eye Institute (NEI) | 2 | 2008-05-01 | 2024-01-05 |
| Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer capecitabine, oxaliplatin, sunitinib malate - Stomach Neoplasms | Phase 1 | Completed | Pfizer | 76 | 2008-05-01 | 2013-01-14 |
Showing 20 of 36. Sign in to see all of them.
Carcinoma, Renal Cell (8) · Breast Neoplasms (3) · Kidney Neoplasms (3) · Stomach Neoplasms (3) · Leukemia, Myeloid, Acute (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Prostatic Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Adenoma, Islet Cell (1) · Breast Neoplasms, Male (1) · Burkitt Lymphoma (1) · Choroidal Neovascularization (1) · Chromosome 5q Deletion Syndrome (1)
National Cancer Institute (NCI) (10) · M.D. Anderson Cancer Center (4) · Pfizer (3) · Roswell Park Cancer Institute (2) · AEterna Zentaris (1) · Australasian Sarcoma Study Group (1) · Bristol-Myers Squibb (1) · Graybug Vision (1) · Harry Drabkin (1) · Icahn School of Medicine at Mount Sinai (1) · Institut Català d'Oncologia (1) · Jaime Merchan (1) · John P. Fruehauf (1) · Jonsson Comprehensive Cancer Center (1) · Ludwig Institute for Cancer Research (1)
United States (30) · Canada (4) · Australia (2) · Spain (2) · Netherlands (1) · South Korea (1)
Glenn Liu (2) · Aung Naing, MD (1) · Bartosz Chmielowski, MD (1) · Brian Rini (1) · Catherine Meyerle, MD (1) · Charles D. Blanke, MD, FACP (1) · Charles P. Semba, MD (1) · David Thomas, MB BS PhD (1) · Emily Chan, MD, PhD (1) · Funda Meric-Bernstam, MD (1) · Harry A. Drabkin, MD (1) · Hope S. Rugo, MD (1)
PMID 19536893, PMID 20818327, PMID 22259028, PMID 22761653, PMID 23660867, PMID 23676418, PMID 24091982, PMID 24158411, PMID 24308791, PMID 24474568, PMID 25732163, PMID 30348216, PMID 31802410, PMID 32337094, PMID 32623479, PMID 33852135, PMID 36184621, PMID 39113428, PMID 39384801
P30CA014520 (2), U01CA062491 (2), U01CA062502 (2), N01CM62201 (1), P30CA043703 (1), P30CA068485 (1), P30CA069533 (1), P30CA072720 (1), U01CA070095 (1), U01CA097452 (1), U01CA121947 (1), U01CA132194 (1), U10CA031946 (1), U10CA180821 (1), UM1CA186689 (1)